Introduction {#sec1}
============

Colon cancer, which originates from malignant transformation of colonic epithelial cells, has become a severe public health threat due to the high incidence and mortality worldwide.[@bib1]^,^[@bib2] There were 1,096,601 estimated new cases and 551,269 estimated deaths of colon cancer in 2018 globally.[@bib2] In 2019 cancer statistics in the United States, colon cancer ranked third in both incidence and mortality.[@bib3] Despite great advances that have been made in surgical resection, chemotherapy, immunotherapy, and so on, the prognosis of about 30% of colon cancer patients is still very poor due to recurrence and/or metastasis.[@bib4]^,^[@bib5] Therefore, revealing the critical molecular events underlying colon cancer recurrence and metastasis to develop more efficient prognostic biomarkers and therapeutic targets is urgently demanded.[@bib6]^,^[@bib7]

The advances of genome and transcriptome high-throughput sequencing have found that the human genome encodes more non-coding RNAs than mRNAs.[@bib8], [@bib9], [@bib10] Among these non-coding RNAs, long non-coding RNA (lncRNA) is a class of transcripts more than 200 nucleotides in length with limited protein coding potential.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15] Increasing evidence has demonstrated that lncRNAs are frequently involved in the initiation and progression of various cancers, including colon cancer.[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21] For example, upregulated lncRNA ITIH4-AS1 promotes proliferation and metastasis of colon cancer via activating JAK/STAT3.[@bib22] lncRNA LINC02418 is highly expressed and may be a diagnostic biomarker for colon cancer.[@bib23] lncRNA CALIC accelerates colon cancer metastasis via upregulating AXL.[@bib24] Although several lncRNAs have been identified to be aberrantly expressed and play corresponding biological roles in colon cancer, the lncRNAs with a predictive value of recurrence and metastasis of colon cancer are still lacking.

In the present study, using gene expression signatures of colon cancers from GEO datasets (<https://www.ncbi.nlm.nih.gov/gds/>), we identified a novel lncRNA (GenBank: [AK095791](ncbi-n:AK095791){#intref0015}), which may predict metastasis and poor prognosis of colon cancer. Therefore, we termed this lncRNA as long non-coding RNA associated with poor prognosis of colon cancer (LNAPPCC). We further investigated the expression pattern and clinical significance of LNAPPCC in colon cancer. Furthermore, gain- and loss-of-function experiments were undertaken to explore the roles of LNAPPCC in colon cancer. Mechanistic investigation identified a positive feedback loop between LNAPPCC, PCDH7, ERK, and c-FOS, which mediate the oncogenic roles of LNAPPCC in colon cancer.

Results {#sec2}
=======

LNAPPCC Is Highly Expressed in Colon Cancer and High Expression of LNAPPCC Is Correlated with Metastasis and Poor Prognosis of Colon Cancer Patients {#sec2.1}
----------------------------------------------------------------------------------------------------------------------------------------------------

To search the lncRNAs involved in colon cancer metastasis, we compared the differentially expressed genes from GSE37892 data, which includes 93 non-metastatic and 37 metastatic colon cancer tissues using GEO2R. Among these differentially expressed genes shown in [Table S1](#mmc2){ref-type="supplementary-material"}, LNAPPCC (probe ID: 232113_at) is the most remarkably upregulated lncRNA with the largest fold-change (FC) value in metastatic colon cancer tissues compared with non-metastatic colon cancer tissues ([Figure 1](#fig1){ref-type="fig"}A). Analyzing the provided clinicopathological characteristics of these 130 colon cancer patients from GSE37892, we found that LNAPPCC expression intensity is higher in stage III colon cancer compared with stage II colon cancer ([Figure 1](#fig1){ref-type="fig"}B). LNAPPCC expression intensity is not correlated with age and tumor location ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The expression of LNAPPCC in 62 pairs of colon cancer tissues and matched adjacent normal tissues was further measured by quantitative real-time PCR. The results found that LNAPPCC is remarkably highly expressed in colon cancer tissues compared with normal tissues ([Figure 1](#fig1){ref-type="fig"}C). Correlation analyses of LNAPPCC expression and clinicopathological characteristics in these 62 colon cancer cases revealed that high expression of LNAPPCC is positively correlated with advanced tumor node metastasis (TNM) stages, but not correlated with age and sex ([Table 1](#tbl1){ref-type="table"}). Compared with normal human colon mucosal epithelial cell line NCM460, the expression of LNAPPCC is also remarkably increased in colon cancer cell lines HT-29, SW620, HCT-15, and HCT116 ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Kaplan-Meier survival analysis was undertaken using GSE39582 and GSE17536 data to detect the correlation between LNAPPCC expression and prognosis. As shown in [Figure 1](#fig1){ref-type="fig"}D, high expression of LNAPPCC is correlated with poor recurrence-free survival in GSE39582 data. Moreover, high expression of LNAPPCC is remarkably correlated with poor overall survival, poor disease specific survival, and more cancer recurrence ([Figures 1](#fig1){ref-type="fig"}E--1G). LNAPPCC is mainly located in the nucleus and poly(A)-positive ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). LNAPPCC full-length sequence was determined with 5′ and 3′ rapid amplification of cDNA ends (RACE) and shown in [Figure S1](#mmc1){ref-type="supplementary-material"}F. Open reading frame (ORF) finder from the National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/orffinder/>) and codon substitution frequency analysis using PhyloCSF calculation on UCSC Genome Browser (<http://genome.ucsc.edu>) both showed that LNAPPCC is a non-coding RNA ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H).Figure 1Expression Pattern and Clinical Significances of LNAPPCC(A) LNAPPCC expression intensities in 93 non-metastatic and 37 metastatic colon cancer tissues from GSE37892 data. p = 0.0059 by Mann-Whitney test. (B) LNAPPCC expression intensities in 73 stage II and 57 stage III colon cancer tissues from GSE37892 data. p = 0.0019 by Mann-Whitney test. (C) LNAPPCC expression levels in 62 pairs of colon cancer tissues and matched adjacent normal tissues were detected by quantitative real-time PCR. p \< 0.0001 by Wilcoxon matched-pairs signed rank test. (D) Kaplan-Meier survival analysis of the correlation between LNAPPCC expression intensities and recurrence free survival from GSE39582 data. n = 577, p = 0.0233 by log-rank test. (E) Kaplan-Meier survival analysis of the correlation between LNAPPCC expression intensities and overall survival from GSE17536 data. n = 177, p = 0.0137 by log-rank test. (F) Kaplan-Meier survival analysis of the correlation between LNAPPCC expression intensities and disease specific survival from GSE17536 data. n = 177, p = 0.0005 by log-rank test. (G) Kaplan-Meier survival analysis of the correlation between LNAPPCC expression intensities and recurrence free survival from GSE17536 data. n = 145, p = 0.0002 by log-rank test.Table 1Correlation between LNAPPCC Expression and Clinicopathological CharacteristicsVariableLNAPPCCp ValueLowHighAge0.442 \>601619 ≤601512Sex0.445 Male1316 Female1815Pathology T stage0.029 T1-2103 T3-42128Pathology N Stage0.030 N02517 N1-2614Pathology M stage0.038 M02923 M128[^2]

LNAPPCC Facilitates Colon Cancer Cell Proliferation and Migration {#sec2.2}
-----------------------------------------------------------------

To observe the potential functions of LNAPPCC in colon cancer, we constructed LNAPPCC stably overexpressed HCT116 and SW620 cells via stable transfection of LNAPPCC mammalian expression plasmid pcDNA/LNAPPCC ([Figures 2](#fig2){ref-type="fig"}A and 2B). Cell counting kit-8 (CCK-8) assays revealed that cell proliferation of both HCT116 and SW620 cells was remarkably increased by LNAPPCC overexpression ([Figures 2](#fig2){ref-type="fig"}C and 2D). The pro-proliferative roles of LNAPPCC were further confirmed by 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay ([Figure 2](#fig2){ref-type="fig"}E). Transwell assays revealed that cell migration of both HCT116 and SW620 cells was remarkably increased by LNAPPCC overexpression ([Figure 2](#fig2){ref-type="fig"}F). To further confirm the oncogenic roles of LNAPPCC, we stably overexpressed LNAPPCC in normal human colon mucosal epithelial cell line NCM460 ([Figure S2](#mmc1){ref-type="supplementary-material"}A). CCK-8 and EdU incorporation assays revealed that overexpression of LNAPPCC also promoted NCM460 cell proliferation ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Transwell assays revealed that overexpression of LNAPPCC also promoted NCM460 cell migration ([Figure S2](#mmc1){ref-type="supplementary-material"}D). LNAPPCC stably silenced HCT116 cells were constructed via stable transfection of two independent LNAPPCC-specific short hairpin RNAs (shRNAs; [Figure 2](#fig2){ref-type="fig"}G). Both CCK-8 and EdU incorporation assays revealed that cell proliferation was remarkably repressed by silencing of LNAPPCC ([Figures 2](#fig2){ref-type="fig"}H and 2I). Furthermore, Transwell assays revealed that cell migration was also remarkably repressed by silencing of LNAPPCC ([Figure 2](#fig2){ref-type="fig"}J). Collectively, these findings suggested that LNAPPCC plays oncogenic roles in colon cancer.Figure 2The Biological Roles of LNAPPCC in Colon Cancer Cell Proliferation and Migration(A) LNAPPCC expression levels in LNAPPCC stably overexpressed and control HCT116 cells. (B) LNAPPCC expression levels in LNAPPCC stably overexpressed and control SW620 cells. (C) Cell proliferation of LNAPPCC stably overexpressed and control HCT116 cells was examined by CCK-8 assays. (D) Cell proliferation of LNAPPCC stably overexpressed and control SW620 cells was examined by CCK-8 assay. (E) Cell proliferation of LNAPPCC stably overexpressed and control HCT116 and SW620 cells was examined by EdU incorporation assay. Scale bars represent 100 μm. (F) Cell migration of LNAPPCC stably overexpressed and control HCT116 and SW620 cells was examined by Transwell migration assay. Scale bars represent 100 μm. (G) LNAPPCC expression levels in LNAPPCC stably silenced and control HCT116 cells. (H) Cell proliferation of LNAPPCC stably silenced and control HCT116 cells was examined by CCK-8 assay. (I) Cell proliferation of LNAPPCC stably silenced and control HCT116 cells was examined by EdU incorporation assay. Scale bars represent 100 μm. (J) Cell migration of LNAPPCC stably silenced and control HCT116 cells was examined by Transwell migration assay. Scale bars represent 100 μm. Data are presented as mean ± SD based on at least three independent biological repeats. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001, by Student's t test (A--F) or one-way ANOVA followed by Dunnett's multiple comparisons test (G--J).

The Expression of LNAPPCC Is Significantly Positively Correlated with that of PCDH7, Whose High Expression Is Also Associated with Metastasis and Poor Prognosis of Colon Cancer Patients {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we investigated the molecular mechanisms mediating the oncogenic roles of LNAPPCC in colon cancer. The candidate targets of LNAPPCC were searched based on the following criteria: (1) the targets are differentially expressed between metastatic and non-metastatic colon cancer tissues from GSE37892 data; (2) the expression of the targets is correlated with LNAPPCC in colon cancer tissues from GSE37892 data; and (3) the expression of the targets is correlated with LNAPPCC in colon cancer tissues from GSE17536 data. Following the above criteria, we identified 13 candidates ([Table S2](#mmc3){ref-type="supplementary-material"}). Among these candidates, we noted PCDF7 (probe ID: 228640_at), which has been reported to modulate tumor metastasis.[@bib25], [@bib26], [@bib27] Consistent with LNAPPCC, PCDH7 is also remarkably increased in metastatic colon cancer tissues compared with non-metastatic colon cancer tissues from GSE37892 data ([Figure 3](#fig3){ref-type="fig"}A). The expression of PCDH7 is remarkably positively correlated with LNAPPCC from both GSE37892 and GSE17536 data, with R value of 0.7844 and 0.6865, respectively ([Figures 3](#fig3){ref-type="fig"}B and 3C). Furthermore, Kaplan-Meier survival analysis showed that consistent with LNAPPCC, high expression of PCDH7 is remarkably correlated with poor overall survival, poor disease specific survival, and more cancer recurrence from GSE17536 data ([Figures 3](#fig3){ref-type="fig"}D--3F). The positive correlation between the expression of PCDH7 and LNAPPCC was further confirmed in GSE39582 data, which includes 566 cases with R value of 0.7268 ([Figure 3](#fig3){ref-type="fig"}G). In our own cohort, the expression of PCDH7 is also remarkable positively correlated with LNAPPCC with R value of 0.7308 ([Figure 3](#fig3){ref-type="fig"}H).Figure 3The Correlation between PCDH7 and LNAPPCC Expression in Colon Cancer Tissues(A) PCDH7 expression intensities in 93 non-metastatic and 37 metastatic colon cancer tissues from GSE37892 data. p = 0.0121 by Mann-Whitney test. (B) The correlation between PCDH7 and LNAPPCC expression intensities from GSE37892 data. n = 130, r = 0.7844, p \< 0.0001 by Spearman correlation analysis. (C) The correlation between PCDH7 and LNAPPCC expression intensities from GSE17536 data. n = 177, r = 0.6865, p \< 0.0001 by Spearman correlation analysis. (D) Kaplan-Meier survival analysis of the correlation between PCDH7 expression intensities and overall survival from GSE17536 data. n = 177, p = 0.0056 by log-rank test. (E) Kaplan-Meier survival analysis of the correlation between PCDH7 expression intensities and disease specific survival from GSE17536 data. n = 177, p = 0.0003 by log-rank test. (F) Kaplan-Meier survival analysis of the correlation between LNAPPCC expression intensities and recurrence free survival from GSE17536 data. n = 145, p = 0.0107 by log-rank test. (G) The correlation between PCDH7 and LNAPPCC expression intensities from GSE39582 data. n = 566, r = 0.7268, p \< 0.0001 by Spearman correlation analysis. (H) The correlation between PCDH7 and LNAPPCC expression levels in 62 colon cancer tissues. r = 0.7308, p \< 0.0001 by Spearman correlation analysis.

LNAPPCC Activates *PCDH7* Expression via Relieving the Repressive Roles of EZH2 on *PCDH7* {#sec2.4}
------------------------------------------------------------------------------------------

PCDH7 was previously reported as a polycomb group target gene.[@bib28] EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3).[@bib29]^,^[@bib30] H3K27me3 is a repressive chromatin marker and represses target gene transcription.[@bib31] Intriguingly, an interaction between LNAPPCC and EZH2 was predicted by the online RNA-protein interaction prediction (RPISeq)[@bib32] (<http://pridb.gdcb.iastate.edu/RPISeq/>) with random forest classifier value of 0.7 and support vector machine classifier value of 0.98 (greater than 0.5 was considered positive). Therefore, we hypothesized that whether the interaction between LNAPPCC and EZH2 regulates the transcription of *PCDH7*. RNA pull-down assays using biotin-labeled LNAPPCC were undertaken in SW620 and HCT116 cells. As shown in [Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A, EZH2 was remarkably enriched in biotin-labeled LNAPPCC group. Furthermore, RNA immunoprecipitation (RIP) assays using EZH2-specific antibody revealed that LNAPPCC was specifically enriched in EZH2 antibody group ([Figure 4](#fig4){ref-type="fig"}B). HOTAIR and GAPDH mRNA was used as positive and negative controls, respectively, for EZH2 binding ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Because EZH2 was reported to bind G-rich motif,[@bib33] we next scanned for G-rich motif in LNAPPCC and identified a G-rich motif in 685--715 nt of LNAPPCC ([Figure 4](#fig4){ref-type="fig"}C). RIP assays showed that the mutation of the G-rich motif abolished the enrichment of LNAPPCC by EZH2 ([Figure 4](#fig4){ref-type="fig"}D). These data showed that LNAPPCC interacts with EZH2. Next, we investigated whether the interaction between LNAPPCC and EZH2 modulates the binding of EZH2 to *PCDH7* promoter and the chromatin structure at *PCDH7* promoter. Chromatin immunoprecipitation (ChIP) assays showed that ectopic expression of LNAPPCC repressed the binding of EZH2 to *PCDH7* promoter and reduced H3K27me3 level at *PCDH7* promoter ([Figure 4](#fig4){ref-type="fig"}E). Conversely, silencing of LNAPPCC increased the binding of EZH2 to *PCDH7* promoter and upregulated H3K27me3 level at *PCDH7* promoter ([Figure 4](#fig4){ref-type="fig"}F). *p16*, which was reported to be a target gene of EZH2, was used as control ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Then, the effects of LNAPPCC on *PCDH7* expression were detected. The mRNA and protein levels of PCDH7 were remarkably increased in LNAPPCC stably overexpressed HCT116 and SW620 cells ([Figures 4](#fig4){ref-type="fig"}G and 4H). Conversely, the mRNA and protein levels of PCDH7 were remarkably decreased in LNAPPCC stably silenced HCT116 cells ([Figure 4](#fig4){ref-type="fig"}I). Therefore, these findings suggested that LNAPPCC activates *PCDH7* expression via reducing the binding and repressive roles of EZH2 on PCDH7 *promoter*.Figure 4LNAPPCC Activates PCDH7 Expression via Binding EZH2(A) RNA pull-down assay using biotin-labeled LNAPPCC was undertaken to detect the interaction between LNAPPCC and EZH2. (B) RIP assay using EZH2 specific antibody was undertaken to detect the binding between EZH2 and LNAPPCC. (C) Schematic outlining the predicted G-rich motif in LNAPPCC and the wild-type (WT) and mutated LNAPPCC sequences used for RIP with anti-EZH2. LNAPPCC-Mut contains a deletion of the G-rich motif. (D) After transient transfection of LNAPPCC-WT or LNAPPCC-Mut overexpression plasmids into HCT116 cells, RIP assay was undertaken using EZH2 specific antibody. (E) ChIP assay using EZH2 and H3K27me3 specific antibodies was undertaken in LNAPPCC stably overexpressed and control SW620 cells to detect the effects of LNAPPCC overexpression on the binding of EZH2 to *PCDH7* promoter and H3K27me3 level at *PCDH7* promoter. (F) ChIP assay using EZH2 and H3K27me3 specific antibodies was undertaken in LNAPPCC stably silenced and control HCT116 cells to detect the effects of LNAPPCC silencing on the binding of EZH2 to *PCDH7* promoter and H3K27me3 level at *PCDH7* promoter. (G) PCDH7 mRNA and protein levels in LNAPPCC stably overexpressed and control HCT116 cells were detected by quantitative real-time PCR and western blot. (H) PCDH7 mRNA and protein levels in LNAPPCC stably overexpressed and control SW620 cells were detected by quantitative real-time PCR and western blot. (I) PCDH7 mRNA and protein levels in LNAPPCC stably silenced and control HCT116 cells were detected by quantitative real-time PCR and western blot. Data are presented as mean ± SD based on at least three independent biological repeats. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ns, not significant, by Student's t test (B, D, E, G, and H) or one-way ANOVA followed by Dunnett's multiple comparisons test (F and I).

PCDH7 Promotes Colon Cancer Cell Proliferation and Migration {#sec2.5}
------------------------------------------------------------

To investigate whether PCDH7 is a mediator of the oncogenic roles of LNAPPCC in colon cancer, we next examined the potential roles of PCDH7 in colon cancer. PCDH7 stably overexpressed HCT116 cells were constructed via stable transfection of PCDH7 mammalian expression plasmid pReceiver/PCDH7 ([Figure 5](#fig5){ref-type="fig"}A). CCK-8 and EdU incorporation assays both revealed that cell proliferation of HCT116 cells was remarkably increased by PCDH7 overexpression ([Figures 5](#fig5){ref-type="fig"}B and 5C). Transwell assays revealed that cell migration of HCT116 cells was also remarkably increased by PCDH7 overexpression ([Figure 5](#fig5){ref-type="fig"}D). PCDH7 stably silenced HCT116 cells were further constructed via stable transfection of two independent PCDH7-specific shRNAs ([Figure 5](#fig5){ref-type="fig"}E). Both CCK-8 and EdU incorporation assays revealed that cell proliferation was remarkably repressed by silencing of PCDH7 ([Figures 5](#fig5){ref-type="fig"}F and 5G). Transwell assays revealed that cell migration was also remarkably repressed by silencing of PCDH7 ([Figure 5](#fig5){ref-type="fig"}H). Therefore, these findings suggested that consistent with LNAPPCC, PCDH7 also plays oncogenic roles in colon cancer.Figure 5The Roles of PCDH7 in Colon Cancer Cell Proliferation and Migration(A) PCDH7 expression levels in PCDH7 stably overexpressed and control HCT116 cells. (B) Cell proliferation of PCDH7 stably overexpressed and control HCT116 cells was examined by CCK-8 assays. (C) Cell proliferation of PCDH7 stably overexpressed and control HCT116 cells was examined by EdU incorporation assay. Scale bars represent 100 μm. (D) Cell migration of PCDH7 stably overexpressed and control HCT116 cells was examined by Transwell migration assay. Scale bars represent 100 μm. (E) PCDH7 expression levels in PCDH7 stably silenced and control HCT116 cells. (F) Cell proliferation of PCDH7 stably silenced and control HCT116 cells was examined by CCK-8 assay. (G) Cell proliferation of PCDH7 stably silenced and control HCT116 cells was examined by EdU incorporation assay. Scale bars represent 100 μm. (H) Cell migration of PCDH7 stably silenced and control HCT116 cells was examined by Transwell migration assay. Scale bars represent 100 μm. Data are presented as mean ± SD based on at least three independent biological repeats. ∗∗p \< 0.01, ∗∗∗p \< 0.001 by Student's t test (B--D) or one-way ANOVA followed by Dunnett's multiple comparisons test (F and H).

PCDH7 Increases *LNAPPCC* Expression via Activating ERK/c-FOS Signaling {#sec2.6}
-----------------------------------------------------------------------

Due to the significant positive correlation between the expression of PCDH7 and LNAPPCC in colon cancer tissues, we next investigated whether PCDH7 could modulate LNAPPCC expression inversely. The expression of LNAPPCC in PCDH7 stably overexpressed and silenced HCT116 cells was detected by quantitative real-time PCR. Intriguingly, LNAPPCC was remarkably increased in PCDH7 overexpressed cells and decreased in PCDH7 silenced cells ([Figure 6](#fig6){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}A). These data suggested that PCDH7 also upregulates LNAPPCC. Previous reports showed that PCDH7 activates mitogen-activated protein kinase (MAPK) signaling in lung cancer.[@bib34]^,^[@bib35] In this study, we further investigated whether PCDH7 also activates MAPK signaling in colon cancer. As shown in [Figures 6](#fig6){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B, ectopic expression of PCDH7 induced ERK and c-FOS activation, and conversely, silencing of PCDH7 repressed ERK and c-FOS activation in colon cancer cells. Searching *LNAPPCC* promoter, we identified a c-FOS binding site located at 460 bp upstream of LNAPPCC transcription initiation site ([Figure 6](#fig6){ref-type="fig"}C). Luciferase reporter assays showed that c-FOS increased LNAPPCC promoter activity ([Figure 6](#fig6){ref-type="fig"}D). ChIP assays showed that ectopic expression of PCDH7 increased the binding of c-FOS to *LNAPPCC* promoter, whereas silencing of PCDH7 decreased the binding of c-FOS to *LNAPPCC* promoter ([Figure 6](#fig6){ref-type="fig"}E; [Figure S4](#mmc1){ref-type="supplementary-material"}C). To investigate whether the upregulation of LNAPPCC by PCDH7 is dependent on the activation of ERK/c-FOS signaling, we treated PCDH7 stably overexpressed HCT116 cells with ERK inhibitor GDC-0994. The results showed that inhibition of ERK activation abrogated the upregulation of LNAPPCC caused by PCDH7 overexpression ([Figure 6](#fig6){ref-type="fig"}F). Thus, these findings suggested that PCDH7 upregulates *LNAPPCC* expression via activating ERK/c-FOS signaling. Combined with the findings that LNAPPCC activates *PCDH7* expression, our data demonstrated that LNAPPCC/PCDH7/ERK/c-FOS form a positive feedback loop in colon cancer ([Figure 6](#fig6){ref-type="fig"}G). Via activating PCDH7/ERK/c-FOS axis, ectopic expression of LNAPPCC increased the binding of c-FOS to *LNAPPCC* promoter, whereas silencing of LNAPPCC decreased the binding of c-FOS to *LNAPPCC* promoter ([Figure 6](#fig6){ref-type="fig"}H; [Figure S4](#mmc1){ref-type="supplementary-material"}D), which further support the LNAPPCC/PCDH7/ERK/c-FOS positive feedback loop. The correlations between LNAPPCC expression, PCDH7 expression, ERK activation, and c-FOS activation were further analyzed in colon cancer tissues. In our cohort containing 62 colon cancer cases, we found that the colon cancer tissues with strong phosphorylated ERK staining have higher expression of LNAPPCC and PCDH7 than the colon cancer tissues with weak phosphorylated ERK staining ([Figures 6](#fig6){ref-type="fig"}I and 6J). The colon cancer tissues with strong phosphorylated c-FOS staining also have higher expression of LNAPPCC and PCDH7 than the colon cancer tissues with weak phosphorylated c-FOS staining ([Figures 6](#fig6){ref-type="fig"}K and 6L).Figure 6PCDH7 Upregulates LNAPPCC Expression via Activating ERK/c-FOS Signaling(A) LNAPPCC expression levels in PCDH7 stably overexpressed and control HCT116 cells. (B) ERK and c-FOS phosphorylation levels in PCDH7 stably overexpressed and control HCT116 cells. (C) Schematic outlining the predicted binding site of c-FOS on *LNAPPCC* promoter. (D) After transient co-transfection of firefly luciferase reporter containing *LNAPPCC* promoter, pRL-TK (encoding renilla luciferase), and c-FOS overexpression plasmid into HCT116 cells, dual luciferase reporter assays were performed. Results were shown as relative ratio of firefly luciferase activity to renilla luciferase activity. (E) ChIP assay using c-FOS specific antibodies was undertaken in PCDH7 stably overexpressed and control HCT116 cells to detect the effects of PCDH7 overexpression on the binding of c-FOS to *LNAPPCC* promoter. (F) LNAPPCC expression levels in PCDH7 stably overexpressed HCT116 cells treated with 1 μM GDC-0994 for 48 h. (G) A schematic model of the LNAPPCC/PCDH7/ERK/c-FOS positive feedback loop. (H) ChIP assay using c-FOS specific antibodies was undertaken in LNAPPCC stably overexpressed and control HCT116 cells to detect the effects of LNAPPCC overexpression on the binding of c-FOS to *LNAPPCC* promoter. (I and J) LNAPPCC (I) and PCDH7 (J) expression levels in 62 colon cancer tissues with strong or weak p-ERK staining intensity. The median p-ERK staining intensity was used as the cutoff. p = 0.0081 (I) and p = 0.0093 (J) by Mann-Whitney test. (K and L) LNAPPCC (K) and PCDH7 (L) expression levels in 62 colon cancer tissues with strong or weak p-c-FOS staining intensity. The median p-c-FOS staining intensity was used as the cutoff. p = 0.0012 (K) and p = 0.0041 (L) by Mann-Whitney test. For (A), (D), (E), (F), and (H), data are presented as mean ± SD based on at least three independent biological repeats. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ns, not significant, by Student's t test (A, D, E, and H) or one-way ANOVA followed by Dunnett's multiple comparisons test (F).

ERK Inhibitor or Depletion of PCDH7 Abrogates the Roles of LNAPPCC in Promoting Colon Cancer Cell Proliferation and Migration {#sec2.7}
-----------------------------------------------------------------------------------------------------------------------------

To examine whether LNAPPCC exerts oncogenic roles via the LNAPPCC/PCDH7/ERK/c-FOS feedback loop in colon cancer, we treated LNAPPCC stably overexpressed HCT116 cells with ERK inhibitor GDC-0994. CCK-8 and EdU incorporation assays revealed that the pro-proliferative roles of LNAPPCC were abolished by ERK inhibitor ([Figures 7](#fig7){ref-type="fig"}A and 7B). Transwell assays revealed that the pro-migratory roles of LNAPPCC were also abolished by ERK inhibitor ([Figure 7](#fig7){ref-type="fig"}C). In addition, PCDH7 was stably silenced in LNAPPCC stably overexpressed HCT116 cells via stable transfection of PCDH7-specific shRNA into LNAPPCC overexpressed HCT116 cells ([Figure 7](#fig7){ref-type="fig"}D). CCK-8 and EdU incorporation assays revealed that the pro-proliferative roles of LNAPPCC were abolished by the silencing of PCDH7 ([Figures 7](#fig7){ref-type="fig"}E and 7F). Transwell assays revealed that the pro-migratory roles of LNAPPCC were also abolished by the silencing of PCDH7 ([Figure 7](#fig7){ref-type="fig"}G). Therefore, these findings suggested that LNAPPCC promotes colon cancer cell proliferation and migration via the positive LNAPPCC/PCDH7/ERK/c-FOS feedback loop.Figure 7The Roles of LNAPPCC in Promoting Colon Cancer Cell Proliferation and Migration Are Dependent on the LNAPPCC/PCDH7/ERK/c-FOS Feedback Loop(A) Cell proliferation of LNAPPCC stably overexpressed HCT116 cells treated with 1 μM GDC-0994 was examined by CCK-8 assays. (B) Cell proliferation of LNAPPCC stably overexpressed HCT116 cells treated with 1 μM GDC-0994 was examined by EdU incorporation assay. Scale bars represent 100 μm. (C) Cell migration of LNAPPCC stably overexpressed HCT116 cells treated with 1 μM GDC-0994 was examined by Transwell migration assay. Scale bars represent 100 μm. (D) PCDH7 expression levels in LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells. (E) Cell proliferation of LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells was examined by CCK-8 assays. (F) Cell proliferation of LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells was examined by EdU incorporation assay. Scale bars represent 100 μm. (G) Cell migration of LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells was examined by Transwell migration assay. Scale bars represent 100 μm. Data are presented as mean ± SD based on at least three independent biological repeats. ∗∗p \< 0.01, ∗∗∗p \< 0.001, ns, not significant, by one-way ANOVA followed by Dunnett's multiple comparisons test.

LNAPPCC Facilitates Colon Cancer Xenograft Growth and Liver Metastasis in a PCDH7-Dependent Manner {#sec2.8}
--------------------------------------------------------------------------------------------------

To investigate the *in vivo* roles of LNAPPCC in colon cancer growth and metastasis, we subcutaneously injected LNAPPCC stably overexpressed HCT116 cells with or without PCDH7 silencing into nude mice. As shown in [Figures 8](#fig8){ref-type="fig"}A--8C, overexpression of LNAPPCC remarkably promoted colon cancer xenograft growth, which was abrogated by the silencing of PCDH7. Overexpression of LNAPPCC and PCDH7 in subcutaneous xenografts derived from LNAPPCC overexpressed HCT116 cells were confirmed ([Figure 8](#fig8){ref-type="fig"}D). Furthermore, the downregulation of LNAPPCC and PCDH7 in subcutaneous xenografts derived from PCDH7-silenced HCT116 cells were also confirmed ([Figure 8](#fig8){ref-type="fig"}D). Ki67 staining of subcutaneous xenografts revealed that overexpression of LNAPPCC promoted colon cancer cell proliferation *in vivo*, which was abolished by the silencing of PCDH7 ([Figure 8](#fig8){ref-type="fig"}E). Phosphorylated ERK and c-FOS staining revealed that overexpression of LNAPPCC activated ERK and c-FOS *in vivo*, which was also abolished by the silencing of PCDH7 ([Figures 8](#fig8){ref-type="fig"}F and 8G; [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). In addition, LNAPPCC stably overexpressed HCT116 cells with or without PCDH7 silencing were intrasplenically injected into nude mice to construct liver metastasis model. As shown in [Figures 8](#fig8){ref-type="fig"}H--8J, overexpression of LNAPPCC remarkably promoted colon cancer liver metastasis, which was abrogated by the silencing of PCDH7. To confirm the roles of LNAPPCC in colon cancer xenograft growth and liver metastasis, we subcutaneously injected LNAPPCC stably silenced HCT116 cells into nude mice. LNAPPCC knockdown remarkably repressed colon cancer xenograft growth ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5E). Downregulation of LNAPPCC and PCDH7 in subcutaneous xenografts derived from LNAPPCC-silenced HCT116 cells were confirmed ([Figure S5](#mmc1){ref-type="supplementary-material"}F). Ki67 staining of subcutaneous xenografts revealed that LNAPPCC knockdown repressed colon cancer cell proliferation *in vivo* ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Phosphorylated ERK and c-FOS staining revealed that LNAPPCC knockdown inactivated ERK and c-FOS *in vivo* ([Figures S5](#mmc1){ref-type="supplementary-material"}H--S5K). In addition, LNAPPCC stably silenced HCT116 cells were intrasplenically injected into nude mice to construct liver metastasis model. As shown in [Figure S5](#mmc1){ref-type="supplementary-material"}L--S5N, LNAPPCC knockdown remarkably inhibited colon cancer liver metastasis.Figure 8LNAPPCC Facilitates Colon Cancer Xenograft Growth and Liver Metastasis(A) LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells were subcutaneously injected into nude mice. Subcutaneous tumor volumes were measured every 7 days. (B) Subcutaneous tumor weights were measured at the 28^th^ day after injection. (C) Image of subcutaneous tumors excised at the 28^th^ day after injection. (D) The expression of LNAPPCC and PCDH7 in subcutaneous tumors. (E) Ki67 IHC staining in subcutaneous tumors. (F) p-ERK IHC staining in subcutaneous tumors. (G) p-c-FOS IHC staining in subcutaneous tumors. (H--J) LNAPPCC stably overexpressed and concurrently PCDH7 stably silenced HCT116 cells were intrasplenically injected into nude mice. At the 35^th^ day after injection, liver metastases of indicated colon cancer cells were detected by H&E staining. Scale bars represent 1,000 μm. Data are presented as mean ± SD based on n = 6 mice in each group. ∗p \< 0.05, ∗∗p \< 0.01, ns, not significant, by Kruskal-Wallis test followed by Dunn's multiple comparisons test.

Discussion {#sec3}
==========

Until now, surgical resection is still the most efficient therapeutic strategy for most colon cancer. However, approximately 30% of colon cancer patients may suffer postoperative recurrence or metastasis.[@bib5] Therefore, identifying predictive biomarkers for colon cancer recurrence and/or metastasis may be beneficial to the early intervention.[@bib36] In this study, we first identified that lncRNA LNAPPCC is remarkably associated with colon cancer recurrence and metastasis using multiple cohorts. Our findings demonstrated that LNAPPCC is highly expressed in colon cancer tissues and cell lines. Increased expression of LNAPPCC is remarkably positively associated with metastasis, recurrence, and poor survival of colon cancer patients.

The gene encoding LNAPPCC is located at chromosome 11q24.1. LNAPPCC has one exon and 2,445 nucleotides in length. Except for the aberrant expression of LNAPPCC in colon cancer, LNAPPCC was also found to play critical roles in colon cancer. Gain-of-function experiments demonstrated that LNAPPCC promotes colon cancer cell proliferation and migration *in vitro* and colon cancer xenograft growth and liver metastasis *in vivo*. Loss-of-function experiments showed that silencing of LNAPPCC inhibits colon cancer cell proliferation and migration *in vitro* and colon cancer xenograft growth and liver metastasis *in vivo*. Thus, our data suggested that LNAPPCC has oncogenic roles in colon cancer and represents a potential therapeutic target for colon cancer.

Molecular mechanisms underlying the roles of lncRNAs are complex and various.[@bib37], [@bib38], [@bib39] Different subcellular locations of lncRNAs implies different molecular mechanisms. For cytoplasmic lncRNAs, they could directly bind proteins, microRNAs (miRs), and/or mRNAs and change the modification, stability, location, and roles of the interacted partners.[@bib40], [@bib41], [@bib42] For nuclear lncRNAs, one of the main mechanisms is to bind epigenetic modification machineries, modulate epigenetic modification and chromatin structure of target genes, and therefore modulate the expression of target genes.[@bib43], [@bib44], [@bib45] Among the epigenetic modification machineries, PRC2, which catalyzes H3K27me3 and represses target genes expression, is frequently involved in the roles of lncRNAs.[@bib46] Several lncRNAs, such as HOTAIR, ANCR, H19, SYISL, AFAP1-AS1 have been reported to bind EZH2, the catalytic subunit PRC2, change genomic location of EZH2, and therefore regulate the expression of target genes.[@bib47], [@bib48], [@bib49], [@bib50], [@bib51] In this study, using bioinformatic analysis and experimental verification, we also found that LNAPPCC binds to EZH2. Although we identified the interaction between LNAPPCC and EZH2, whether the interaction is direct or indirect needs further investigation. In multiple cohorts, we found a remarkably positive correlation between the expression of LNAPPCC and PCDH7. PCDH7 has been reported to be a PRC2 target. In this study, we further found that via interacting with EZH2, LNAPPCC suppresses the binding of EZH2 to *PCDH7* promoter, reduces H3K27me3 level at *PCDH7* promoter, and thus upregulates *PCDH7* expression. PCDH7, also known as protocadherin 7, belongs to the cadherin superfamily. PCDH7 has been reported to have oncogenic roles in lung cancer and breast cancer via activating MAPK or PLCβ-Ca^2+^/CaMKII/S100A4 signaling.[@bib26]^,^[@bib34] In this study, we found that PCDH7 also plays oncogenic roles in colon cancer via activating MAPK-c-FOS signaling. Except PCDH7, whether LNAPPCC regulate the expression of other genes via interacting with EZH2 needs further investigation.

Except for the positive regulation of PCDH7 by LNAPPCC, we further found that PCDH7 could positively regulate LNAPPCC via activated ERK and c-FOS signaling. LNAPPCC was identified as a transcription target of c-FOS. Therefore, LNAPPCC, PCDH7, ERK, and c-FOS form a positive feedback loop. In clinical colon cancer tissues, we also found significant positive correlation between LNAPPPCC expression, PCDH7 expression, ERK phosphorylation level, and c-FOS phosphorylation level. The positive feedback loop could amplify the effects of participants. Several feedback loops have been reported to be employed by cancer cells to exert their malignant behaviors, such as ERIC/E2F, miR-200a/HDAC4, SNHG14/miR-5590-3p/ZEB1, NF90/lncRNA-LET/miR-548k, and so on.[@bib52], [@bib53], [@bib54], [@bib55] Functional rescue experiments showed that inhibition of ERK activation or silencing of PCDH7 abrogated the oncogenic roles of LNAPPCC in colon cancer, which suggested that the LNAPPCC/PCDH7/ERK/c-FOS feedback loop at least partially mediates the oncogenic roles of LNAPPCC in colon cancer.

In summary, this study identified a novel oncogenic lncRNA LNAPPCC, which is upregulated in colon cancer and correlated with metastasis, recurrence, and poor prognosis of colon cancer patients. LNAPPCC facilitates colon cancer cell proliferation and migration *in vitro* and colon cancer growth and liver metastasis *in vivo* via activating the LNAPPCC/PCDH7/ERK/c-FOS positive feedback loop. Our findings suggested LNAPPCC as a potential predictive biomarker for colon cancer metastasis and recurrence. Our results also suggested that targeting LNAPPCC/EZH2/PCDH7/ERK/c-FOS feedback loop represents a potential therapeutic strategy for colon cancer.

Materials and Methods {#sec4}
=====================

Clinical Samples {#sec4.1}
----------------

A total of 62 pairs of colon cancer tissues and matched adjacent normal tissues were collected from colon cancer patients who received surgery at Hainan General Hospital. Postoperatively, the clinical samples were histopathologically staged following the TNM system. The clinicopathological characteristics of these 62 colon cancer patients are shown in [Table 1](#tbl1){ref-type="table"}. Written informed consent was obtained from each patient. This study was carried out in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hainan General Hospital.

Cell Culture and Treatment {#sec4.2}
--------------------------

Normal human colon mucosal epithelial cell line NCM460 and colon cancer cell lines HT-29, SW620, HCT-15, and HCT116 were purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). NCM460 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (GIBCO). HT-29 and HCT116 cells were grown in McCoy's 5a medium (Sigma). SW620 cells were grown in L-15 medium (GIBCO). HCT-15 cells were grown in RPMI-1640 medium (GIBCO). All cells were cultured in the above described medium complemented with 10% fetal bovine serum (GIBCO) in a moist air with 5% CO~2~ at 37°C. Where indicated, cells were treated with 1 μM GDC-0994 (Selleck) for the indicated time.

Quantitative Real-Time PCR {#sec4.3}
--------------------------

Total RNA was extracted from tissues and cells using RNAiso Plus (Takara) following the provided protocol. Subsequently, the RNA was reverse-transcribed into first strand complementary DNA (cDNA) with PrimeScript 1st strand cDNA Synthesis Kit (Takara). The cDNA was then used to undertake quantitative real-time PCR with TB Green Premix Ex Taq II (Takara) on StepOne Plus System (Applied Biosystems, Foster City, CA, USA). GAPDH was used as endogenous control. The primer sequences used for quantitative real-time PCR were as follows: for LNAPPCC: 5′-TTCGGACACAGAAGGACA-3′ (sense) and 5′-GGAAACAGAGGCAAAAAAG-3′ (antisense); for PCDH7: 5′-ATCTACCACCAGCCAACA-3′ (sense) and 5′-ACTCACAACAGAAAACGTCA-3′ (antisense); for HOTAIR: 5′-TTCCACAGACCAACACCC-3′ (sense) and 5′-CTAAATCCGTTCCATTCCA-3′ (antisense); for GAPDH: 5′-GGTCTCCTCTGACTTCAACA-3′ (sense) and 5′-GTGAGGGTCTCTCTCTTCCT-3′ (antisense); for β-actin: 5′-GGGAAATCGTGCGTGACATTAAG-3′ (sense) and 5′-TGTGTTGGCGTACAGGTCTTTG-3′ (antisense); and for U6: 5′-GCTTCGGCAGCACATATACTAAAAT-3′ (sense) and 5′-CGCTTCACGAATTTGCGTGTCAT-3′ (antisense). The relative expressions levels of RNAs were calculated by the 2^−ΔΔCt^ method.

Isolation of Cytoplasmic, Nuclear, and Poly(A)-Positive RNA {#sec4.4}
-----------------------------------------------------------

Cytoplasmic and nuclear fractions were isolated and harvested by the cytoplasmic and nuclear RNA purification kit (Norgen). The RNA present in the subcellular fractions was detected by quantitative real-time PCR. Poly(A)-positive RNA was enriched by the GenElute mRNA Miniprep Kit (Sigma) and then detected by quantitative real-time PCR.

5′ and 3′ Rapid Amplification of cDNA Ends (RACE) {#sec4.5}
-------------------------------------------------

The transcriptional initiation and termination sites of LNAPPCC were determined by 5′ and 3′ RACE analyses with SMARTer RACE cDNA Amplification Kit (Clontech) according to the manufacturer's manual. The primer sequences used for quantitative real-time PCR were as follows: for 5′ RACE, 5′-CCTGTTATCACTGAAAATCACGGAAGA-3′ and for 3′ RACE, 5′-CTGACTACACTACCGATGATGCTGGC-3′.

Plasmids Construction and Transfection {#sec4.6}
--------------------------------------

Full-length LNAPPCC was PCR-amplified from cDNA with the primers 5′-GGGGTACCTTTGATTGTCGAGTCATCGT-3′ (sense) and 5′-GGAATTCTCAGCAAGGAATGTCTTTAACAAG-3′ (antisense). Subsequently, the PCR products were subcloned into the KpnI and EcoR I sites of pCDNA3.1(+) backbone to construct LNAPPCC mammalian expression plasmid pcDNA/LNAPPCC. G-rich motif mutated LNAPPCC expression plasmid pcDNA/LNAPPCC-Mut (mutant) was synthesized by GenScript. Furthermore, the PCR products were also subcloned into the KpnI and EcoR I sites of pSPT19 backbone to construct LNAPPCC *in vitro* transcription plasmid pSPT19/LNAPPCC. Two independent cDNA oligonucleotides suppressing LNAPPCC expression (shLNAPPCC-1 and shLNAPPCC-2) were synthesized and inserted into the supersilencing shRNA expression vector pGPU6/Neo (GenePharma, Shanghai, China). A scrambled shRNA (shCtrl) was used as negative control. The shRNA sequences were as follows: for shLNAPPCC-1: 5′-CACCGCTGCCAAATTATACGAATGCTTCAAGAGAGCATTCGTATAATTTGGCAGCTTTTTTG-3′ (sense) and 5′-GATCCAAAAAAGCTGCCAAATTATACGAATGCTCTCTTGAAGCATTCGTATAATTTGGCAGC-3′ (antisense); for shLNAPPCC-2: 5′-CACCGGGCATTATTGATACTGATCTTTCAAGAGAAGATCAGTATCAATAATGCCCTTTTTTG-3′ (sense) and 5′-GATCCAAAAAAGGGCATTATTGATACTGATCTTCTCTTGAAAGATCAGTATCAATAATGCCC-3′ (antisense); for shCtrl: 5′-CACCGTTCTCCGAACGTGTCACGTCAAGAGATTACGTGACACGTTCGGAGAATTTTTTG-3′ (sense) and 5′-GATCCAAAAAATTCTCCGAACGTGTCACGTAATCTCTTGACGTGACACGTTCGGAGAAC-3′ (antisense). *LNAPPCC* promoter was PCR-amplified from DNA with the primers 5′-GGGGTACCATTGTTAGATGGGATCAGG-3′ (sense) and 5′-CCGCTCGAGGGACTATCAAAGACTGGA-3′ (antisense). Subsequently, the PCR products were subcloned into the KpnI and Xho I sites of pGL3-Basic vector (Promega) to construct firefly luciferase reporter containing *LNAPPCC* promoter. PCDH7 mammalian expression plasmid pReceiver/PCDH7 was purchased from GeneCopoeia (EX-Y4988-M02). c-FOS mammalian expression plasmid pReceiver/c-FOS was purchased from GeneCopoeia (EX-B0247-M02). The corresponding empty plasmid pReceiver-M02 was used as negative control. The shRNA suppressing PCDH7 expression (shPCDH7) was purchased from GeneCopoeia (HSH062195-mH1). The corresponding shRNA scrambled control was purchased from GeneCopoeia (CSHCTR001-mH1). Another shRNA targeting PCDH7 (shPCDH7-2) was purchased from GenePharma. Plasmids transfection was undertaken using Lipofectamine 3000 (Invitrogen) according to the manufacturer's manual.

Cell Proliferation Assays {#sec4.7}
-------------------------

Cell proliferation was evaluated by CCK-8 and EdU incorporation assays. For CCK-8 assay, 2,000 indicated colon cancer cells/well were seeded into 96-well plates and cultured for 1, 2, 3, or 4 days. At indicated time, each well was added with 10 μL of CCK-8 reagent (Dojindo Laboratories) and incubated for another 2 h. Subsequently, the absorbance values at 450 nm were collected using a standard microplate reader. EdU incorporation assay was undertaken using the Cell-Light EdU *In Vitro* Kit (RiboBio) following the manufacturer's manual. The images of EdU-positive cells were collected using a fluorescence microscope (Carl Zeiss).

Cell Migration Assay {#sec4.8}
--------------------

Cell migration was evaluated by Transwell migration assay. 50,000 indicated colon cancer cells were plated in the upper chamber of 24-well Transwell inserts (BD Biosciences) supplemented with serum-free medium. Lower chambers were added with medium supplemented with 10% fetal bovine serum (GIBCO). The inserts were further incubated in 5% CO~2~ at 37°C for another 48 h. Then, the cells remaining on the upper chambers were removed, and the migratory cells were fixed and stained by crystal violet. The number of migratory cells was counted using a fluorescence microscope (Carl Zeiss).

RNA Pull-Down Assay {#sec4.9}
-------------------

LNAPPCC was *in vitro* transcribed and biotinylated from pSPT19/LNAPPCC using Biotin RNA Labeling Mix (Roche) and T7 RNA polymerase (Roche) according to the manufacturer's manual. 3 μg of biotinylated and refolded LNAPPCC was incubated with 1 mg protein extracts from indicated colon cancer cells and Dynabeads Myone Streptavidin T1 beads (Invitrogen) overnight. Subsequently, the beads were washed three times. After streptavidin bead pull-down, the enriched proteins were detected by western blot.

Western Blot {#sec4.10}
------------

Cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime) added with protease inhibitor (Selleck) and phosphatase inhibitor (Selleck). The extracted or enriched proteins were separated by 12% SDS-PAGE. After being transferred into polyvinylidene fluoride (PVDF) membrane (Millipore), the blots were incubated with primary antibodies against EZH2 (1:500; 07-689; Millipore), PCDH7 (1:200; ab139274; Abcam), phospho-ERK1/2 (1:1,000; \#4370; Cell Signaling Technology), ERK1/2 (1:1,000; \#4695; Cell Signaling Technology), phospho-c-FOS (1:1,000; \#5348; Cell Signaling Technology), c-FOS (1:1,000; \#2250; Cell Signaling Technology), or GAPDH (1:10,000; T0004; Affinity). After three washes, the blots were further incubated with goat anti-mouse immunoglobulin G (IgG) H&L (IRDye 680RD) preadsorbed secondary antibody (1:10,000; ab216776; Abcam) or goat anti-rabbit IgG H&L (IRDye 800CW) preadsorbed secondary antibody (1:10,000; ab216773; Abcam). The western blot images were obtained using Odyssey infrared scanner (Li-Cor).

RIP {#sec4.11}
---

RIP experiment was undertaken with the EZ-Magna RIP RNA-binding protein immunoprecipitation kit (Millipore) and EZH2 specific antibody (5 μg; 07-689; Millipore) following the manufacturer's manual. Enriched RNA was measured by quantitative real-time PCR.

ChIP {#sec4.12}
----

ChIP experiment was undertaken with the EZ-Magna ChIP A/G chromatin immunoprecipitation kit (Millipore) and specific antibodies against EZH2 (5 μg; 07-689; Millipore), H3K27me3 (5 μg; ab6002; Abcam), or Phospho-c-FOS (5 μg; \#5348; Cell Signaling Technology) following the manufacturer's manual. Enriched DNA was measured by quantitative real-time PCR. The primer sequences were as follows: for *PCDH7* promoter: 5′-TTTGTTAATTGCCGTTGGGG-3′ (sense) and 5′-TCTTGCACGCTCTCTCTCC-3′ (antisense); for *LNAPPCC* promoter: 5′-ATAACACCCAAACTGTAC-3′ (sense) and 5′-GGCCCAATAATACGAAAA-3′ (antisense); for *p16* promoter: 5′-GCCCAGTCCTCCTTCCTT-3′ (sense) and 5′-CCCTGTCCCTCAAATCCTC-3′ (antisense).

Luciferase Reporter Assay {#sec4.13}
-------------------------

c-FOS overexpression plasmid, firefly luciferase reporter containing *LNAPPCC* promoter, and pRL-TK plasmid that expressed renilla luciferase were co-transfected into HCT116 cells. 48 h after transfection, the luciferase activities were measured by Dual-Luciferase Reporter Assay System (Promega). The relative firefly luciferase activity was normalized to renilla luciferase activity.

Xenograft Experiment {#sec4.14}
--------------------

Indicated colon cancer cells (5 × 10^6^) were subcutaneously injected into 5- to 6-week-old athymic BALB/c nude mice. Subcutaneous xenograft growth was recorded every 7 days with a caliper, and tumor volume was calculated as 0.5 × a × b^2^ (a, longest diameter; b, shortest diameter). At the 28^th^ day after injection, the mice were sacrificed and the subcutaneous tumors were resected, photographed, and weighed. For liver metastasis experiment, indicated colon cancer cells (2 × 10^6^) were intrasplenically injected into 5- to 6-week-old athymic BALB/c nude mice. At the 35^th^ day after injection, the mice were sacrificed and the livers were resected. The metastatic nodules were detected by hematoxylin and eosin (H&E) staining. Xenograft experiments were approved by the Ethics Committee of Hainan General Hospital.

Immunohistochemistry (IHC) {#sec4.15}
--------------------------

Subcutaneous xenograft and human colon cancer tissues were formalin-fixed and paraffin-embedded. Paraffin sections were used to perform Ki67, phospho-ERK1/2, ERK1/2, phospho-c-FOS, c-FOS IHC staining with primary antibodies against Ki67 (1:200; ab16667; Abcam), phospho-ERK1/2 (1:400; \#4370; Cell Signaling Technology), ERK1/2 (1:250; \#4695; Cell Signaling Technology), phospho-c-FOS (1:100; ab63444; Abcam), or c-FOS (1:1,000; ab208942; Abcam). After washes, the sections were further incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody and visualized with 3,3-diaminobenzidine.

Statistical Analysis {#sec4.16}
--------------------

Statistical analysis was undertaken using GraphPad Prism 6 software. Comparisons were calculated using Mann-Whitney test, Wilcoxon matched-pairs signed rank test, Pearson chi-square test, log-rank test, Student's t test, and one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test, Spearman correlation analysis, or Kruskal-Wallis test followed by Dunn's multiple comparisons test as indicated in the figure legends. p value \< 0.05 was considered significant.
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